Source - RNS
RNS Number : 9407L
Beximco Pharmaceuticals Ltd
07 October 2016



7th October, 2016



Notification of Preliminary Results and Annual General Meeting



Beximco Pharmaceuticals Ltd. (or "Company"; LSE-AIM: BXP) today announces information for the shareholders of the Company that the Board of Directors at their meeting held on 6th October 2016 has decided the following:




Recommended Dividend for the period of 18 months ended on 30th June, 2016


5% final cash dividend i.e. Taka 0.50 per share, in addition to 10% interim cash and 5% stock dividend recommended by the Board of Directors of the Company on April 20, 2016 having record date as May 12, 2016.


With 10% interim cash dividend already paid, the cumulative dividend for the period amounts to 15% cash and 5% stock.


Record date



The Record date for entitlement of 5% final cash dividend will be November 1, 2016. The Shareholders whose names appear in the Share Register of the Company or in the Depository Register on the record date i.e. November 1, 2016 will be entitled to receive the 5% final cash dividend.


5% stock dividend will be entitled by the shareholders whose names appeared in the Share Register of the Company or in the Depository Register on the earlier declared record date i.e. May 12, 2016.


Date & Time of 40th AGM


19 November, 2016 at 10.30 AM


Venue of 40th AGM


Beximco Industrial Park, Sarabo,

Kashimpur, Gazipur.


The Financial highlights for the 18 months period ended on 30 June, 2016:

Jan 15- Jun 16 (18 months)

Jan 16- Jun 16 (6 months)

Jan 15 - Dec 15 (12 months)

Jan 14- Dec 14 (12 months)

Profit before Tax (Taka in thousand)





Profit After Tax

(Taka in thousand)





Earnings Per Share (Taka)





Net Asset Value per Share (NAV)

As on Jun 30, 2016:  Taka 59.70

As on Dec 31, 2014: Taka 56.87

Net Operating Cash flow per Share

For Jan 15 - Jun 16 (18 months) :    Taka 8.21

For Jan 14- Dec 14 (12 months)  :   Taka 6.02


For further information please visit or enquire to:


Beximco Pharma

Nazmul Hassan MP, Managing Director

Tel: +880 2 58611001, ext.20080


Md. Asad Ullah, FCS, Executive Director & Company Secretary

Tel; +880 2 58611891, +880 2 58612040, Ext 10140


SPARK Advisory Partners Limited (Nominated Adviser)

Mark Brady / Sean Wyndham-Quin

Tel: +44 (0)20 3368 3551 / 3555


FTI Consulting

Simon Conway / Victoria Foster Mitchell

Tel: +44 (0)20 3727 1000



Notes to Editors


About Beximco Pharmaceuticals Limited

Founded in 1976 and based in Dhaka, Bangladesh, Beximco Pharma manufactures and sells generic pharmaceutical formulation products and active pharmaceutical ingredients. The Company also undertakes contract manufacturing for multinational and leading global generic pharmaceutical companies. The Company operates from a 23 acre site in Dhaka and has manufacturing facilities for producing various drugs in different delivery systems such as tablets, capsules, liquids, semi-solids, intravenous fluids, metered dose inhalers, dry powder inhalers, sterile ophthalmic drops, prefilled syringes, injectables, nebulizer solutions, oral soluble films etc. Ensuring access to quality medicines is the powerful aspiration that motivates 3,000 employees of the Company.


Beximco Pharma's state-of-the-art manufacturing facilities are certified by global regulatory authorities of Australia, Europe, Latin America, Canada and the US, among others. The Company's products are sold to retail outlets, medical institutions and other pharmaceutical manufacturers in Bangladesh, in regional markets such as Sri Lanka, Nepal, Bhutan, Vietnam, Cambodia and Myanmar and in other markets overseas, principally in Africa, including South Africa, Mauritius, Kenya, Ghana, Ethiopia and Nigeria; Pacific Island; Latin and Central American countries; Middle East, Central Asia, South East Asia, including Singapore, Malaysia, Indonesia, Philippines and Hong Kong; Europe, Including Austria, Germany and Romania and Austria and Australia.

This information is provided by RNS
The company news service from the London Stock Exchange